NFE2L2 and cancer: Accumulating evidence has shown that Nrf2 is activated by mutations in 30% of tumors, viz., lung, liver, head, neck, oral, pancreatic, etc. This transcription factor has a specific oncogenic role in these cancers by modulating redox signaling [105,109,110,119,185].